

Curriculum Vitae

Personal information **Sandra Bright**

Work experience

1. Employer: HPRA
 - Start date: 07/2016
 - End date:
 - Position: Clinical Assessor
 - Activities: Responsibility for assessment of clinical dossiers for clinical trials and medicinal products submitted for national, mutual recognition, decentralised and centralised European marketing approval.
 - Country: Ireland
2. Employer: Trinity Biomedical Sciences Institute, TCD
 - Start date: 09/2014
 - End date: 06/2016
 - Position: Senior Research Fellow
 - Activities: Cell biologist for a large inorganic chemistry laboratory. Biological development and applications of nanomaterials and imaging agents for cancer detection
 - Country: Ireland
3. Employer: Trinity Biomedical Sciences Institute, TCD
 - Start date: 03/2011
 - End date: 09/2014
 - Position: Post Doctoral Research Fellow
 - Activities: Photodynamic therapy for use in cancer.
 - Country: Ireland

Education and training

1. Subject: School of Biochemistry and Immunology, Trinity College Dublin
 - Start date: 10/2005
 - End date: 10/2009
 - Qualification: PhD (Research)
 - Organisation: Oncology and Drug Development
 - Country: Ireland
2. Subject: Trinity College Dublin
 - Start date: 10/2001
 - End date: 05/2005
 - Qualification: Bachelor of Arts Degree in Natural Sciences; B.A.(Mod)
 - Organisation: Biochemistry, Immunology
 - Country: Ireland

Additional information

Publications

1. Water_soluble amphiphilic ruthenium(ii) polypyridyl complexes as potential light_activated therapeutic agents. Estalayo_Adrián S, Blasco S, Bright SA, McManus GJ, Orellana G, Williams DC, Kelly JM, Gunnlaugsson T. Chem Commun (Camb). 2020 Aug 21;56(65):9332_9335.
2. Design, Synthesis and Biochemical Evaluation of Novel Ethanoanthracenes and Related Compounds to Target Burkitt's Lymphoma. Byrne AJ, Bright SA, McKeown JP, O'Brien JE, Twamley B, Fayne D, Williams DC, Meegan MJ. Pharmaceuticals (Basel). 2020 Jan 17;13(1):16.
3. Synthesis and evaluation of antiproliferative microtubule_destabilising combretastatin A_4 piperazine conjugates. O'Boyle NM, Ana G, Kelly PM, Nathwani SM, Noorani S, Fayne D, Bright SA, Twamley B, Zisterer DM, Meegan MJ. Org Biomol Chem. 2019 Jun 26;17(25):6184_6200.
4. Selected nitrostyrene compounds demonstrate potent activity in chronic lymphocytic leukaemia cells, including those with poor prognostic markers. Bright SA, Byrne AJ, Vandenberghe E, Browne PV, Mcelligott AM, Meegan MJ, Williams DC. Oncol Rep. 2019 May;41(5):3127_3136.
5. Synthesis, Antiproliferative and Pro_Apoptotic Effects of Nitrostyrenes and Related Compounds in Burkitt's Lymphoma. Byrne AJ, Bright SA, Fayne D, McKeown JP, McCabe T, Twamley B, Williams C, Meegan MJ. Med Chem. 2018 Feb 6;14(2):181_199.
6. The development of ruthenium(ii) polypyridyl complexes and conjugates for in vitro cellular and in vivo applications. Poynton FE, Bright SA, Blasco S, Williams DC, Kelly JM, Gunnlaugsson T. Chem Soc Rev. 2017 Dec 11;46(24):7706_7756.
7. Novel Selective Estrogen Receptor Ligand Conjugates Incorporating Endoxifen_Combretastatin and Cyclofenil_Combretastatin Hybrid Scaffolds: Synthesis and Biochemical Evaluation. Kelly PM, Keely NO, Bright SA, Yassin B, Ana G, Fayne D, Zisterer DM, Meegan MJ. Molecules. 2017 Aug 31;22(9).
8. 2_Nitroimidazole based fluorescent probes for nitroreductase; monitoring reductive stress in cellulo. Ao X, Bright SA, Taylor NC, Elmes RBP. Org Biomol Chem. 2017 Aug 7;15(29):6104_6108
9. Luminescent Lanthanide Cyclen_Based Enzymatic Assay Capable of Diagnosing the Onset of Catheter_Associated

Urinary Tract Infections Both in Solution and within Polymeric Hydrogels. Surender EM, Bradberry SJ, Bright SA, McCoy CP, Williams DC, Gunnlaugsson T. J Am Chem Soc. 2017 Jan 11;139(1):381_388.

10. Glycosidase activated release of fluorescent 1,8_naphthalimide probes for tumor cell imaging from glycosylated 'pro_probes'. Calatrava_Pérez E, Bright SA, Achermann S, Moylan C, Senge MO, Veale EB, Williams DC, Gunnlaugsson T, Scanlan EM. Chem Commun (Camb). 2016 Nov 18;52(89):13086_13089.

11. Luminescent ruthenium polypyridyl complexes with extended 'dppz' like ligands as DNA targeting binders and cellular agents. Poulsen BC, Estalayo_Adrián S, Blasco S, Bright SA, Kelly JM, Williams DC, Gunnlaugsson T. Dalton Trans. 2016 Nov 15;45(45):18208_18220.

12. Synthesis, antiproliferative and pro_apoptotic activity of 2_phenylindoles. Kelly PM, Bright SA, Fayne D, Pollock JK, Zisterer DM, Williams DC, Meegan MJ. Bioorg Med Chem. 2016 Sep 15;24(18):4075_4099.

13. The novel pyrrolo_1,5_benzoxazepine, PBOX_15, synergistically enhances the apoptotic efficacy of imatinib in gastrointestinal stromal tumours; suggested mechanism of action of PBOX_15. Kinsella P, Greene LM, Bright SA, Pollock JK, Butini S, Campiani G, Bauer S, Williams DC, Zisterer DM. Invest New Drugs. 2016 Apr;34(2):159_67.

14. Unconventional Knoevenagel_type indoles: Synthesis and cell_based studies for the identification of pro_apoptotic agents. Spallarossa A, Caneva C, Caviglia M, Alfei S, Butini S, Campiani G, Gemma S, Brindisi M, Bright SA, Williams CD, Crespan E, Maga G, Sanna G, Delogo I, Collu G, Loddio R. Eur J Med Chem. 2015 Sep 18;102:648_60.

15. Detailed Biological Profiling of a Photoactivated and Apoptosis Inducing pddpz Ruthenium(II) Polypyridyl Complex in Cancer Cells. Cloonan SM, Elmes RB, Erby M, Bright SA, Poynton FE, Nolan DE, Quinn SJ, Gunnlaugsson T, Williams DC. J Med Chem. 2015 Jun 11;58(11):4494_505.

16. Supramolecular approach to enantioselective DNA recognition using enantiomerically resolved cationic 4_amino_1,8_naphthalimide_based Tröger's bases. Banerjee S, Bright SA, Smith JA, Bugeat J, Martinez_Calvo M, Williams DC, Kelly JM, Gunnlaugsson T. J Org Chem. 2014 Oct 3;79(19):9272_83.

17. Synthesis, photophysical and cytotoxicity evaluations of DNA targeting agents based on 3_amino_1,8_naphthalimide derived Tröger's bases. Murphy S, Bright SA, Poynton FE, McCabe T, Kitchen JA, Veale EB, Williams DC, Gunnlaugsson T. Org Biomol Chem. 2014 Sep 14;12(34):6610_23.

18. The novel pyrrolo_1,5_benzoxazepine, PBOX_6, synergistically enhances the apoptotic effects of carboplatin in drug sensitive and multidrug resistant neuroblastoma cells. Lennon JC, Bright SA, Carroll E, Butini S, Campiani G, O'Meara A, Zisterer DM. Biochem Pharmacol. 2014 Feb 15;87(4):611_24.

19. Synthesis and antiproliferative action of a novel series of maprotiline analogues. McNamara YM, Bright SA, Byrne AJ, Cloonan SM, McCabe T, Williams DC, Meegan MJ. Eur J Med Chem. 2014 Jan;71:333_53.

20. Synthesis, spectroscopic and biological studies of a fluorescent Pt(II) (terpy) based 1,8_naphthalimide conjugate as a DNA targeting agent. Banerjee S, Kitchen JA, Bright SA, O'Brien JE, Williams DC, Kelly JM, Gunnlaugsson T. Chem Commun (Camb). 2013 Oct 4;49(76):8522_4.

21. Combretazet_3 a novel synthetic cis_stable combretastatin_A_4_azetidinone hybrid with enhanced stability and therapeutic efficacy in colon cancer. Greene LM, Wang S, O'Boyle NM, Bright SA, Reid JE, Kelly P, Meegan MJ, Zisterer DM. Oncol Rep. 2013 Jun;29(6):2451_8.

22. Basic N_interlinked imipramines show apoptotic activity against malignant cells including Burkitt's lymphoma. Bright SA, Brinkø A, Larsen MT, Sinning S, Williams DC, Jensen HH. Bioorg Med Chem Lett. 2013 Mar 1;23(5):1220_4.

23. Photophysical and biological investigation of novel luminescent Ru(II)_polypyridyl_1,8_naphthalimide Tröger's bases as cellular imaging agents. Elmes RB, Erby M, Bright SA, Williams DC, Gunnlaugsson T. Chem Commun (Camb). 2012 Mar 7;48(20):2588_90.

24. The vascular targeting agent combretastatin_A4 and a novel cis_Restricted {beta}_Lactam Analogue, CA_432, induce apoptosis in human chronic myeloid leukemia cells and ex vivo patient samples including those displaying multidrug resistance. Greene LM, Nathwani SM, Bright SA, Fayne D, Croke A, Gagliardi M, McElligott AM, O'Connor L, Carr M, Keely NO, O'Boyle NM, Carroll P, Sarkadi B, Conneally E, Lloyd DG, Lawler M, Meegan MJ, Zisterer DM. J Pharmacol Exp Ther. 2010 Nov;335(2):302_13.

25. Sequential treatment with flavopiridol synergistically enhances pyrrolo_1,5_benzoxazepine_induced apoptosis in human chronic myeloid leukaemia cells including those resistant to imatinib treatment. Bright SA, Campiani G, Deininger MW, Lawler M, Zisterer DM. Biochem Pharmacol. 2010 Jul 1;80(1):31_8.

26. Novel pyrrolo_1,5_benzoxazepine compounds display significant activity against resistant chronic myeloid leukaemia cells in vitro, in ex vivo patient samples and in vivo. Bright SA, McElligott AM, O'Connell JW, O'Connor L, Carroll P, Campiani G, Deininger MW, Conneally E, Lawler M, Zisterer DM. Br J Cancer. 2010 May 11;102(10):1474_82.

27. Evidence for cross_regulated cytokine response in human peripheral blood mononuclear cells exposed to whole gonococcal bacteria in vitro. Rarick M, McPheeters C, Bright S, Navis A, Skefos J, Sebastiani P, Montano M. Microb Pathog. 2006 Jun;40(6):261_70.

Projects

Memberships

Other Relevant Information